The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Idorsia Ltd stock forecast from 0 analysts, the average analyst target price for Idorsia Ltd is not available over the next 12 months. Idorsia Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Idorsia Ltd is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Idorsia Ltd’s stock price was CHF 1.75. Idorsia Ltd’s stock price has changed by -18.25% over the past week, -20.84% over the past month and -59.18% over the last year.
No recent analyst target price found for Idorsia Ltd
No recent average analyst rating found for Idorsia Ltd
Company Overview Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia. The company has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and commercialize PIVLAZ. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland. Address: Hegenheimermattweg 91, Allschwil, Switzerland, 4123 Read Less
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunol...Read More
Frequently Asked Questions About Idorsia Ltd (IDIA:SW) Stock
Stock Target Advisor's fundamental analysis for Idorsia Ltd's stock is Slightly Bearish.
Unfortunately we do not have enough data on IDIA:SW's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on IDIA:SW's stock to indicate what its average analyst target is.
IDIA:SW stock's Price/Earning ratio is 10.71.
Our analysis grades IDIA:SW stock's Price / Earning ratio at F. This means that IDIA:SW stock's Price/Earning ratio is above 43.00000000000001% of the stocks in the Biotechnology sector in the SW exchange.
Based on this IDIA:SW may be fairly valued for its sector
The last closing price of IDIA:SW's stock was CHF 1.75.
The most recent market capitalization for IDIA:SW is CHF 0.33B.
Unfortunately we do not have enough analyst data on IDIA:SW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Idorsia Ltd's stock.
As per our most recent records Idorsia Ltd has 0 Employees.
Idorsia Ltd's registered address is Hegenheimermattweg 91, Allschwil, Switzerland, 4123.
You can get more information about it from Idorsia Ltd's website at https://www.idorsia.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Idorsia Ltd (IDIA:SW) Stock
Stock Target Advisor's fundamental analysis for Idorsia Ltd's stock is Slightly Bearish.
Unfortunately we do not have enough data on IDIA:SW's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on IDIA:SW's stock to indicate what its average analyst target is.
IDIA:SW stock's Price/Earning ratio is 10.71.
Our analysis grades IDIA:SW stock's Price / Earning ratio at F. This means that IDIA:SW stock's Price/Earning ratio is above 43.00000000000001% of the stocks in the Biotechnology sector in the SW exchange.
Based on this IDIA:SW may be fairly valued for its sector
The last closing price of IDIA:SW's stock was CHF 1.75.
The most recent market capitalization for IDIA:SW is CHF 0.33B.
Unfortunately we do not have enough analyst data on IDIA:SW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Idorsia Ltd's stock.
As per our most recent records Idorsia Ltd has 0 Employees.
Idorsia Ltd's registered address is Hegenheimermattweg 91, Allschwil, Switzerland, 4123.
You can get more information about it from Idorsia Ltd's website at https://www.idorsia.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IDIA:SW !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
